Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 83 Matches

Pyrimethamine

Model Files Publication

Brand Name(s) include: Daraprim

Disease: Malaria

Drug Class: Antimalarials

Date Updated: November 2021

Model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 2) Note: Kp scalar used
Route of Elimination	Non-specific hepatic metabolism (metabolizing enzymes not known)
Perpetrator DDI	OCT1 and OCT2 inhibitor
Validation	Three clinical studies were available for model verification. 100% of simulated Cmax and AUC were within 1.5-fold of observed and hence the model performance was deemed acceptable.
Limitations	The current model does not describe enzyme specific metabolism of pyrimethamine as there are no data for specific routes of metabolism. The current model does not mechanistically describe the absorption of pyrimethamine as the ADAM model over-predicts the extent of absorption. Although pyrimethamine is described as well absorbed in some literature, further analysis of the IV and PO data did not support this.
Updates in V19	Updated in vitrodata fup: 0.085 -> 0.095

Search Score: 1

Creatinine_MechKiM_V16R1_UniversityOfManchester_20210421

Model Files Publication

https://doi.org/10.1124/jpet.118.251413 Creatinine compound file with MechKiM

Search Score: 1

Capmatinib_V19R1_Pfizer_20210804

Model Files Publication

An optimized Rosuvastatin (V19) model was used and DDIs predominantly driven by gut BCRP inhibition are reasonably recovered. Altogether, the following inhibitors were used: Capmatinib Fenebrutinib Fostamatinib Itraconazole Zepatier The workspace represents the DDI between Rosuvastatin and Capmatinib. Note: The fuGut in the inhibitor file is set as user input to 1. A minimal PBPK model with VSAC is used. Link to the publication with further details: http://doi.org/10.1002/psp4.12672

Search Score: 1

Fenebrutinib_V19R1_Pfizer_20210804

Model Files Publication

An optimized Rosuvastatin (V19) model was used and DDIs predominantly driven by gut BCRP inhibition are reasonably recovered. Altogether, the following inhibitors were used: Capmatinib Fenebrutinib Fostamatinib Itraconazole Zepatier The workspace represents the DDI between Rosuvastatin and Fenebrutinib. Notes: - The fuGut in the inhibitor file is set as user input to 1. - An additional systemic clearance of 1.1 L/h is included in the submitted file. Link to the publication with further details: http://doi.org/10.1002/psp4.12672

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Pyrimethamine

Model at-a-glance

Creatinine_MechKiM_V16R1_UniversityOfManchester_20210421

Capmatinib_V19R1_Pfizer_20210804

Fenebrutinib_V19R1_Pfizer_20210804

Your Privacy